Trial
NCT01622088
Phase 3 Extension Study of Dexpramipexole in ALS
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Knopp Biosciences
Collaborators
Biogen
Condition
Amyotrophic Lateral Sclerosis
Intervention
Dexpramipexole
Why stopped
The Initial Phase 3 Study (NCTO1281189) did not meet its primary efficacy endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-05-03